Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study
Por:
Kamp, D, May, AM, Adenis, A, Capela, A, Derks, S, De Felice, F, Dovnik, NF, Hierro, C, Ilhan-Mutlu, A, Lordick, F, Obermannova, RL, Petrillo, A, Puccini, A, Raimundo, A, Roviello, G, Siebenhüner, A, Slingerland, M, Smyth, EC, Laarhoven, HWMV and Mohammad, NH
Publicada:
11 mar 2025
Ahead of Print:
1 feb 2025
Resumen:
Background: The enhanced application of imaging techniques is resulting in the diagnosis of more patients with asymptomatic metastatic esophagogastric cancer (mEGC). We conducted a Delphi study to gather insights from European experts on the optimal timing for initiating palliative systemic therapy for these patients. Methods: An online survey featured 14 scenarios where physicians chose their preferred timing for initiating systemic therapy: immediate(<3 weeks) or deferred. The standard scenario was a 65-year-old male, WHO/ECOG 0 with asymptomatic mEGC, 2 metastases in each lung, HER2 -, PDL1-CPS 2. In every subsequent case, one characteristic was modified. To investigate the fortitude of the physicians' preference for an immediate start, scenarios also included a patient who was motivated to start but preferred to defer if the physician deemed it judicious. Consensus was defined as >= 75 % agreement; scenarios without consensus were re-evaluated in Delphi round 2. Results: Thirty-nine physicians participated in the first round, and 33 in the second round. Consensus to start treatment immediately was reached in 12 (86 %) scenarios. When patients preferred to defer, the consensus was to still advise to start palliative systemic treatment immediately in half (n = 7) of the scenarios. Only 2 scenarios (pre-existent WHO/ECOG 2 or 78 years old) reached the consensus that treatment could be deferred. Conclusions: In asymptomatic mEGC, immediate start of treatment is preferred by European experts. Consensus was established that treatment can be deferred for patients who prefer deferral and either have a pre-existent WHO/ECOG performance status of 2 or are of advanced age.
Filiaciones:
Kamp, D:
Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
May, AM:
Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
Adenis, A:
Inst Canc Montpellier, Med Oncol Dept, Montpellier, France
Capela, A:
Unidade Local Saude Gaia & Espinho, Dept Med Oncol, Villa Nova De Gaia, Portugal
Derks, S:
Free Univ Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
Canc Ctr Amsterdam, Canc Treatment & Qual Life, Amsterdam, Netherlands
De Felice, F:
Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Policlin Umberto 1, Rome, Italy
Dovnik, NF:
Univ Med Ctr Maribor, Dept Oncol, Maribor, Slovenia
:
Univ Autonoma Barcelona, Catalan Inst Oncol ICO Badalona, Med Oncol Dept, Barcelona 08916, Spain
Ilhan-Mutlu, A:
Med Univ Vienna, Dept Med 1, Clin Div Oncol, Vienna, Austria
Lordick, F:
Univ Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germany
Obermannova, RL:
Masaryk Univ, Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic
Masaryk Univ, Masaryk Mem Canc Inst, Fac Med, Brno, Czech Republic
Petrillo, A:
Osped Mare, Med Oncol Unit, Via E Russo, Naples, Italy
Puccini, A:
Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy
IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Milan, Italy
Raimundo, A:
CUF Tejo Lisbon, Dept Med Oncol, Lisbon, Portugal
Roviello, G:
Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Florence, Italy
Slingerland, M:
Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
Smyth, EC:
Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England
Hirslanden Zurich AG, Clin Hematol & Oncol, Zurich, Switzerland
Univ Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
Green Submitted, Green Published, hybrid
|